Howanitz P J
Department of Pathology and Laboratory Medicine, University of California-Los Angeles Medical Center 90095-1713, USA.
Arch Pathol Lab Med. 1995 Oct;119(10):979-83.
Implementation of the conference consensus that alternative site testing should be under the direction of the laboratory director supported by an institutional structure of users, laboratorians, and possibly administrators will optimize success. Information is needed if, when, and where alternative site testing improves the care of patients, and if faster results are associated with better and less expensive patient care. Costs and the timeliness of both central clinical laboratory and alternative site testing must be estimated in an identical fashion, then both must be compared with the costs and timeliness attributed to all steps of the total testing process included. As has been done with glucose, accuracy and precision goals must be developed for analytes measured at alternative test sites, then agreement reached on what these goals are and whether speed of measurement can influence these goals. Consideration of successful models is essential by those implementing or reevaluating alternative site testing programs. Required scientific information cannot be obtained in a timely manner unless improved funding occurs.
会议达成的共识是，替代检测点的检测应由实验室主任指导，并得到用户、检验人员以及可能的管理人员组成的机构架构的支持，实施这一共识将优化成功率。需要了解替代检测点检测在何时、何地以及是否能改善患者护理，以及更快的检测结果是否与更好且成本更低的患者护理相关。必须以相同的方式估算中央临床实验室和替代检测点检测的成本及及时性，然后将两者与整个检测过程所有步骤的成本和及时性进行比较。正如对血糖检测所做的那样，必须为在替代检测点测量的分析物制定准确性和精密度目标，然后就这些目标是什么以及测量速度是否会影响这些目标达成一致。实施或重新评估替代检测点检测项目的人员必须考虑成功的模式。除非增加资金投入，否则所需的科学信息无法及时获取。
